National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2014 (No. 2) (PB 80 of 2014) (Cth)

PB 80 of 2014

National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2014 (No. 2)

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 84AG(1) of the National Health Act 1953.

Dated          25     September 2014

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2014 (No. 2).

(2)     This Determination may also be cited as PB 80 of 2014.

1. Commencement

This Determination commences on 1 October 2014.

3              Amendments to PB 1 of 2010

Schedule 1 amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010).

Schedule 1             Amendments

[1]      Section 4 Definitions

omit:

Statins-HP group means the HMG Co-A reductase inhibitor higher potency group.

[2]      Schedule 1, Part 2

omit:

1	Candesartan
3	Irbesartan

[3]      Omit entry for Schedule 1, Part 7